Claims for Patent: 7,727,968

Summary for Patent: 7,727,968

Title:	Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
Abstract:	Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.
Inventor(s):	Feingold; Jay Marshall (Wynnewood, PA), Sherman; Matthew L. (Newton, MA), Leopold; Lance H. (Dresher, PA), Berger; Mark (Merion Station, PA)
Assignee:	Wyeth LLC (Madison, NJ)
Application Number:	11/811,626
Patent Claims:	1. A method of treating acute leukemia or myelodysplastic syndrome consisting essentially of administering to a patient in need of treatment thereof: (a) gemtuzumab ozogamicin in an amount of about 3 mg/m.sup.2 to about 9 mg/m.sup.2 per day; (b) daunorubicin in an amount of about 45 mg/m.sup.2 to about 60 mg/m.sup.2 per day; and (c) cytarabine in an amount of about 100 mg/m.sup.2 to about 200 mg/m.sup.2 per day. 2. The method according to claim 1, wherein the amount of gemtuzumab ozogamicin is 6 mg/m.sup.2 per day. 3. The method according to claim 1, wherein the daunorubicin is daunorubicin hydrochloride. 4. The method according to claim 1 or 3, wherein the amount of daunorubicin is 45 mg/m.sup.2 per day. 5. The method according to claim 1, wherein the amount of cytarabine is 100 mg/m.sup.2 per day. 6. A method of treating acute leukemia or myelodysplastic syndrome consisting essentially of administering to a patient in need of treatment thereof: (a) gemtuzumab ozogamicin in an amount of about 3 mg/m.sup.2 to 9 mg/m.sup.2 for one day; (b) daunorubicin in an amount of about 45 mg/m.sup.2 to 60 mg/m.sup.2 per day for three days; and (c) cytarabine in an amount of about 100 mg/m.sup.2 to 200 mg/m.sup.2 per day for at least seven days. 7. The method according to claim 6, wherein the daunorubicin is administered to the patient on the first three days that cytarabine is administered to the patient. 8. The method according to claim 6 or 7, wherein the gemtuzumab ozogamicin is administered to the patient on the fourth day that cytarabine is administered to the patient. 9. The method according to claim 6, wherein the cytarabine is administered for ten days. 10. The method according to claim 8, wherein the cytarabine is administered by continuous infusion, the daunorubicin is administered by intravenous bolus, and the gemtuzumab ozogamicin is administered by 2-hour infusion. 11. The method according to claim 8, wherein the cytarabine is administered in an amount of 100 mg/m.sup.2/day, the daunorubicin is administered in an amount of 45 mg/m.sup.2, and the gemtuzumab ozogamicin is administered in an amount of 6 mg/m.sup.2. 12. The method according to claim 6, wherein the daunorubicin is daunorubicin hydrochloride. 13. A pharmaceutical combination for enhanced induction of remission in a patient having acute leukemia or myelodysplastic syndrome consisting essentially of gemtuzumab ozogamicin in an amount of about 3 mg/m.sup.2 to about 9 mg/m.sup.2, daunorubicin in an amount of about 45 mg/m.sup.2 to about 60 mg/m.sup.2, and cytarabine in an amount of about 100 mg/m.sup.2 to about 200 mg/m.sup.2. 14. The pharmaceutical combination of claim 13, wherein the daunorubicin is daunorubicin hydrochloride. 15. The pharmaceutical combination of claim 13 wherein the gemtuzumab ozogamicin is in an amount of about 6 mg/m.sup.2. 16. The pharmaceutical combination of claim 13 or 14, wherein the daunorubicin is in an amount of about 45 mg/m.sup.2. 17. The pharmaceutical combination of claim 13, wherein the cytarabine is in an amount of 100 mg/m.sup.2. 18. A pharmaceutical combination for enhanced induction of remission in a patient having acute leukemia or myelodysplastic syndrome consisting essentially of gemtuzumab ozogamicin in an amount of 6 mg/m.sup.2, daunorubicin in an amount of 45 mg/m.sup.2, and cytarabine in an amount of 100 mg/m.sup.2. 19. A method of treating acute myelogenous leukemia or myelodysplastic syndrome consisting essentially of: (a) administering a first course of therapy to a patient in need of treatment consisting essentially of: (i) gemtuzumab ozogamicin in an amount of about 3 mg/m.sup.2 to about 9 mg/m.sup.2 per day for one day; (ii) daunorubicin in an amount of about 45 mg/m.sup.2 to about 60 mg/m.sup.2 per day for up to three days; and (iii) cytarabine in an amount of about 100 mg/m.sup.2 to about 200 mg/m.sup.2 per day for up to ten days; (b) administering a second course of therapy to a patient in need of treatment consisting essentially of: (i) gemtuzumab ozogamicin in an amount of about 3 mg/m.sup.2 to about 9 mg/m.sup.2 per day for one day; (ii) daunorubicin in an amount of about 45 mg/m.sup.2 to about 60 mg/m.sup.2 per day for up to three days; and (iii) cytarabine in an amount of about 100 mg/m.sup.2 to about 200 mg/m.sup.2 per day for up to ten days; and (c) administering a third course of therapy to a patient in need of treatment consisting essentially of: (i) daunorubicin in an amount of about 45 mg/m.sup.2 to about 60 mg/m.sup.2 per day for up to three days; and (ii) cytarabine in an amount of about 100 mg/m.sup.2 to about 200 mg/m.sup.2 per day for up to ten days. 20. A method of treating acute myelogenous leukemia or myelodysplastic syndrome consisting essentially of: (a) administering a first course of therapy to a patient in need of treatment consisting essentially of: (i) gemtuzumab ozogamicin in an amount of 6 mg/m.sup.2 per day for one day; (ii) daunorubicin in an amount of 45 mg/m.sup.2 per day for up to three days; and (iii) cytarabine in an amount of 100 mg/m.sup.2 to about 200 mg/m.sup.2 per day for up to ten days; (b) administering a second course of therapy to a patient in need of treatment consisting essentially of: (i) gemtuzumab ozogamicin in an amount of 6 mg/m.sup.2 per day for one day; (ii) daunorubicin in an amount of 45 mg/m.sup.2 to per day for up to three days; and (iii) cytarabine in an amount of 100 mg/m.sup.2 per day for up to ten days; and (c) administering a third course of therapy to a patient in need of treatment consisting essentially of: (i) daunorubicin in an amount of 45 mg/m.sup.2 per day for up to three days; and (ii) cytarabine in an amount of 100 mg/m.sup.2 per day for up to ten days.

Details for Patent 7,727,968

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Wyeth Pharmaceuticals Llc	MYLOTARG	gemtuzumab ozogamicin	For Injection	761060	09/01/2017		2022-11-06